[HTML][HTML] Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update

R Roskoski Jr - Pharmacological research, 2023 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Small molecule kinase inhibitor drugs (1995–2021): medical indication, pharmacology, and synthesis

CC Ayala-Aguilera, T Valero… - Journal of Medicinal …, 2021 - ACS Publications
The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

The role of JAK/STAT signaling pathway and its inhibitors in diseases

P Xin, X Xu, C Deng, S Liu, Y Wang, X Zhou… - International …, 2020 - Elsevier
The JAK/STAT signaling pathway is an universally expressed intracellular signal
transduction pathway and involved in many crucial biological processes, including cell …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

R Roskoski Jr - Pharmacological research, 2020 - Elsevier
Because genetic alterations including mutations, overexpression, translocations, and
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway …

H Zhu, Z Jian, Y Zhong, Y Ye, Y Zhang, X Hu… - Frontiers in …, 2021 - frontiersin.org
Background Inflammatory responses play a multiphase role in the pathogenesis of cerebral
ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces …

Properties of FDA-approved small molecule protein kinase inhibitors

R Roskoski Jr - Pharmacological research, 2019 - Elsevier
Because mutations, overexpression, and dysregulation of protein kinases play essential
roles in the pathogenesis of many illnesses, this enzyme family has become one of the most …

Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19

W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020 - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update

R Roskoski Jr - Pharmacological research, 2021 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers

R Roskoski Jr - Pharmacological research, 2019 - Elsevier
The EGFR family is among the most investigated receptor protein-tyrosine kinase groups
owing to its general role in signal transduction and in oncogenesis. This family consists of …

Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: From mechanism to therapy

J Liu, X Han, T Zhang, K Tian, Z Li, F Luo - Journal of Hematology & …, 2023 - Springer
Inflammation is a fundamental defensive response to harmful stimuli, but the overactivation
of inflammatory responses is associated with most human diseases. Reactive oxygen …